22.11.2022 - UPPSALA, SE / ACCESSWIRE / November 22, 2022 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) Biovica, active in cancer monitoring, today announces that the unique study design of the TK IMPACT trial, using the DiviTum® TKa blood .
CDK1,
BUB1) play important roles in the progression of G2/M phase in the cell cycle.
30,31 Furthermore, real-time PCR analysis was used to verify the results of transcriptome sequencing and the results indicated that the expression trends of the top 18 ranked degree genes were consistent with those obtained by RNA-seq, suggesting that the RNA-seq data reliably reflected the gene expression alterations (Figure 4B). According to the RNA-seq and real-time PCR results, the expressions of cell cycle regulated genes, such as
CDK1,
PLK1, and
BUB1, were significantly decreased after sinomenine treatment. These results were also in accord with the cell phenotype experiments.